Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer

International Journal of Gastrointestinal Cancer

Volumn 34, Issue 2-3, 2004, Pages 79-86

  Garcia, Agustin A ^a,e   Leichman, Lawrence ^b   Baranda, Joaquina ^c   Pandit, Lalita ^d   Lenz, Heinz Josef ^a   Leichman, Cynthia G ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Salick Health Care Inc   (United States)

^c Cancer Center of Irvine   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

5 fluorouracil; Chemotherapy; Leucovorin; Pancreatic cancer; Trimetrexate

Indexed keywords

FLUOROURACIL; FOLINIC ACID; TRIMETREXATE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HYPOKALEMIA; MALE; NAUSEA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; SURVIVAL TIME; VOMITING;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIARRHEA; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; NAUSEA; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIMETREXATE; VOMITING;

EID: 4644257764     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Jemal A, Thomas A, Murray T, et al. Cancer Statistics. CA Cancer J Clin 2002;52:23-47.
2. Ahlgren JD. Chemotherapy for pancreatic cancer. Cancer 1996;78:654-663.
3. Carter SK, Comis RL. The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev 1975; 2:193-214.
4. Cullinan S, Moertel CG, Wieand HS, et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990;65:2207-2212.
5. Rougier M, Ducreux M, Douillard, JY, et al. Efficacy of 5FU + cisplatin (FUP) compared to bolus 5FU (FU) in advanced pancreatic carcinoma (APC): a randomized trial from the French Anticancer Centers Digestive Group (FNL-CCDG). Proc Am Soc Clin Oncol 1999;18:1050 (abstract).
6. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
7. Rothenberg M, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-353.
8. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Inv New Drugs 1994;12: 29-34.
9. Carmichael J, Fink U, Russell RCG, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1995;73:101-105.
10. Heinemann V. Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 2001;60:8-18.
11. Martin DS. Introduction to 5-fluorouracil modulation. Cancer Invest 1990;8:257-258.
12. Peters GJ, Schornagel JH, Milano GA. Clinical pharmacokinetics of antimetabolites. Cancer Surveys 1993;17: 123-149.
13. Fleming GF, Schilsky RL. Antifolates: the next generation. Sem Oncol 1992; 19:707-719.
14. Pyrhonen S, Kuitunen T, Nyandoto P, et al. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Brit J Can 1995;71:587-591.
15. Advanced colorectal cancer meta-analysis project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994;12:960-969.
16. Lin JT, Bertino JR. Update of trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties. Cancer Inv 1991;9:159-172.
17. Jackson RC, Leopold WR, Hamelehle KL, et al. Preclinical studies with trimetrexate: a review of conclusions and unanswered questions. Sem Oncol. 1988;15:1-7.
18. Romanini A, Li WW, Colofiore JR, et al. Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells. JNCI 1992;84:1033-1038.
19. Elliot WL, Howard CT, Dykes DJ, et al. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice. Cancer Res 1989;49:5586-5590.
20. Sobrero A, Romanini A, Russello O, et al. Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction. Eur J Can Clin Oncol 1989;25:977-982.
21. Conti JA, Kemeny N, Seiter K, et al. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol 1994;12:695-700.
22. Blanke CD, Kasimis B, Schein P, et al. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol 1997;15:915-920.
23. Szelenyi H, Hohenberger P, Lochs H, et al. Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO. Oncology 2000;58: 273-279.
24. Cullinan SA, Moertel CG, Fleming TR. et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985;253:2061-2067.
25. Takada T, Kato H, Matsushiro T, et al. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994;51:396-400.
26. Cullinan S, Moertel CG, Wieand HS, et al. A phase III trial on the therapy of advanced pancreatic carcinoma: evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990; 65:2207-2212.
27. Gastrointestinal Tumor Study Group. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group. J Clin Oncol 1986;4:1794-1798.
28. Oster MW, Gray R, Panasci L, et al. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer 1986;57:29-33.
29. Louvet C, Andre T, Hammel P, et al. A. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Ann Oncol 2001;12(5):675-679.
30. Marantz A, Jovtis S, Almira E, et al. Grupo de Tumores Gastrointestinales. Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer. Sem Oncol 2001;28(3 suppl 10):44-49.
31. Rauch DP, Maurer CA, Aebi S, et al. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer. Oncology 2001;60(1):43-48.
32. Kurtz JE, Kohser F, Negrier S, et al. Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study. Hepato-Gastroenterology 2000;47(35): 1450-1453.
33. Oettle H, Arning M, Pelzer U, et al. A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Ann Oncol 2000;11(10):1267-1272.
34. Matano E, Tagliaferri P, Libroia A, et al. Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study. Brit J Can 2000;82(11): 1772-1775.
35. Berlin JD, Adak S, Vaughn DJ, et al. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). Oncology 2000;58(3):215-218.
36. Reni M, Passoni P, Panucci MG, et al. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 2001;19(10):2679-2686.
37. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20(15):3270-3275.
38. Petty RD, Nicolson MC, Skaria S, et al. A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity. Ann Oncol 2003;14(7):1100-1105.
39. Maisey N, Chau I, Cunningham D, et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002;20(14):3130-3136.
40. Storniolo AM, Enas MH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999;85:1261-1268.
41. Jabboury K, Wong A, Hendricks S, et al. Phase I/II weekly sequential trimetrexate and 24-hour fluorouracil/leucovorin infusion in advanced malignancy. Proc Amer Assoc Can Res 1999;40:553(abstract).
42. Cartwright TH, Cohn A, Varkey JA, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002;20(1):160-164.
43. Campos LT, Alvarez RH, Sanford M, et al. Gemcitabine (GEM) and capecitabine (CPC) in advanced pancreatic cancer (APC) and solid tumors. A single institution experience. Proc Am Soc Clin Oncol 2001;20:2315(abstract).
44. Scheithauer W, Schull B, Ulrich-Pur H, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 2003; 14(1):97-104.